Genelux Corporation Announces New Chief Financial Officer

Company Overview - Genelux Corporation is a late-stage clinical biopharmaceutical company focused on developing next-generation oncolytic immunotherapies for aggressive and difficult-to-treat solid tumors [6] - The company's most advanced product candidate, Olvi-Vec, is currently being evaluated in a Phase 3 trial for platinum-resistant/refractory ovarian cancer [6] Leadership Appointment - Matthew Pulisic has been appointed as the new Chief Financial Officer of Genelux, effective January 30, 2025 [1] - Pulisic brings over 19 years of finance and commercial experience in the biopharmaceutical industry, having held senior roles across the United States, Europe, and Asia [2][3] - His previous role was Vice President of Finance at Arrowhead Pharmaceuticals, where he contributed to the company's financial direction and operational improvements [3] Financial Strategy - Pulisic expressed excitement about joining Genelux and aims to advance the company's financial strategy and enhance shareholder value [4] - As part of his appointment, he received an inducement award of stock options to purchase 275,000 shares at an exercise price of $3.95 per share, vesting over four years [5]